Surgeries & Interventions
March 31, 2025
Abbott Enters Burgeoning IVL Segment March 31, 2025
Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but it’s now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbott’s new IVL Investigational Device Exemption (IDE) from the FDA. Abbott’s new IVL IDE was two years in the making following its $890M acquisition of Cardiovascular Systems in 2023 […]
Cardiology Pharmaceuticals
March 27, 2025
Ezetimibe Plus Statins Equals Better Outcomes March 27, 2025
New results from a vast Mayo Clinic meta-analysis suggest that combining ezetimibe with statins to lower LDL-C could have significant mortality and MACE benefits over statin monotherapy. Digging through decades of data from PubMed, Embase, and ClinicalTrials.gov, researchers pooled all relevant articles published through June 2024 (108k patients) and found that a combination lipid-lowering therapy […]
Cardiology Pharmaceuticals
March 24, 2025
Amvuttra Arrives for ATTR-CM with a High Asking Price March 24, 2025
It’s not surprising that Alnylam’s Amvuttra (vutrisiran) received FDA approval for ATTR-CM last week, but what shocked many was Alnylam’s choice to price the drug at nearly half a million dollars per year in a segment where its incumbent competitors cost half as much. Alnylam claims Amvuttra’s eyewatering price stems from the drug’s “compelling and […]
